Elevance Health (NYSE:ELV) just dropped its Q4 earnings, and it's a mixed bag. Revenue climbed 6% to $45 billion, fueled by higher premium yields and a 19% surge in its Carelon division. But medical costs? Still a major headache. Net income took a 50% hit, landing at $418 million, as Medicaid-related expenses kept rising. The benefit expense ratio shot up to 92.4%, a clear sign that the company is still dealing with a flood of Medicaid patients catching up on postponed care.
Despite the cost surge, Elevance gave investors something to cheer about: a 5% dividend boost to $1.71 per share. CEO Gail Boudreaux doubled down on the company's strategy, emphasizing operational improvements and a push for long-term growth. The 2025 outlook? Adjusted EPS projected between $34.15 and $34.85, signaling confidence in navigating industry pressures. But the Medicaid drag is realmembership dipped by 1.1 million, now sitting at 45.7 million.
Investors responded positively, sending Elevance shares higher post-earnings. The big question: Can Elevance keep costs in check while leveraging premium hikes, acquisitions, and Carelon's expansion? The long-term play looks solid, but short-term turbulence is far from over.
This article first appeared on GuruFocus.免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。